Home › Companies › CRVO

CervoMed

Market cap $22.7M 15.1M shares (10-Q, Nov 4, 2026) × $1.50 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Neflamapimod RESTORE topline2H 2026Neflamapimod RESTORE topline, 2H 2026, material
  2. nfvPPA 80 mg BID UK1Q 2027nfvPPA 80 mg BID UK, 1Q 2027, notable
  3. EXPERTS-ALS trial start1Q 2027EXPERTS-ALS trial start, 1Q 2027, routine
  4. Cash runway guidance update~3Q 2027Cash runway guidance update, ~3Q 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (1)

Capital (as filed)

Cash
$6.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$13.5M Sep 30, 2026
Operating cash flow
−$5.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$19.6M cash, runway ~Q3 2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Offering documents (3)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (18)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (18 calls)

Every verdict Biotech Distilled has published on CervoMed, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch CervoMed (CRVO): Scientific Due Diligence for Neflamapimod The science is plausible but the company must raise capital imminently; wait for the inevitable dilutive financing to reprice the stock before entering.
  2. Watch UPDATE: CervoMed (CRVO) – The Bad Batch Fix is In... CMC update confirms the polymorph fix with hard PK data, but the dilution gap remains; wait for the financing before entering.
  3. Watch UPDATE: CervoMed (CRVO) – Annual Report Drops 10-K confirms tightening dilution gap and a narrowing liver safety margin; wait for the financing and dilution before re-evaluating.
  4. Watch UPDATE: CervoMed (CRVO) – The 6-Month Warning and the Smoking Gun in Copenhagen PK/PD data from Copenhagen proves the Bad Batch theory, but the 6-month cash runway makes a financing imminent; stay on the watch list until the raise happens.
  5. Watch UPDATE: CervoMed (CRVO) – Global Regulatory Blessing and Biological Proof at Roth Global regulatory alignment (FDA/EMA/MHRA) and MRI/PET biological proof strengthen the asset, but the financing must happen first before entry.
  6. Watch UPDATE: CervoMed (CRVO) - The Brain Scans Just Got Randomized Blinded placebo-controlled MRI data strengthens the biological case, but the dilution gap remains the binding constraint; the trigger is still the announced financing.
  7. Watch UPDATE: CervoMed (CRVO) - The Q1 10-Q Confirms the Countdown Q1 10-Q shows $12.9M cash and ~5 months of runway with deferred offering costs accumulating, confirming the financing is imminent; maintain watch list until the raise is announced.
  8. Avoid UPDATE: CervoMed (CRVO) - The Bag Got Secured. Sort Of. The $10.5M stopgap PIPE was warrant-laden, insider-heavy, and far too small to fund Phase 3, with the company formally pivoting to a partner-or-bust strategy; the de-risked entry point does not yet exist.
  9. Avoid UPDATE: CervoMed (CRVO) — Same Data, Louder Font The H.C. Wainwright summit deck contains no new clinical data or partner announcement; the company remains partner-or-bust and the AVOID call is unchanged.
  10. Avoid UPDATE: CervoMed (CRVO) — Stopgap #2, A 2042 Patent, and a +71% Tape A second $10M raise in eight days and a 2042 use patent improve the asset but confirm the company cannot self-fund Phase 3; chasing a 71% move into an active ATM is the inverse of the Sniper trade.
  11. Avoid UPDATE: CervoMed (CRVO) — The AAIC Receipts and the 80 mg BID Safety Read AAIC data tightens the efficacy narrative and partially defuses the liver-tox concern, but no partner has arrived and the partner-or-bust setup is unchanged.
  12. Avoid UPDATE: CervoMed (CRVO) — The UK Just Handed Them a Fast Lane The UK ILAP Innovation Passport improves the asset's commercial profile but is a process designation, not a partner; the AVOID call holds until a signed term sheet arrives.
  13. Watch UPDATE: CervoMed (CRVO) — The Going Concern Flag Just Came Down The Q2 10-Q removes the going-concern warning with $24.9M cash and runway through Q3 2027, satisfying the sole precondition for the Sniper setup, though no partner has yet signed.
  14. Watch UPDATE: CervoMed (CRVO) - The Speed Limit Comes Off FDA lifted the plasma exposure cap and a new stable-crystal 100 mg BID tablet improves the asset's sellability, but no partner has signed and the liver risk increased with the higher dose.
  15. Watch UPDATE: CervoMed (CRVO) - The nfvPPA Signal Is a Whisper, Not a Shout The 12-week nfvPPA NfL readout is directionally encouraging but statistically unproven with a second liver discontinuation; the partner trigger remains unchanged.
  16. Watch UPDATE: CervoMed (CRVO) - The Peer-Reviewed Number Is Smaller Peer-reviewed RewinD-LB data confirms the Bad Batch exposure-response story but the pure-DLB effect size is smaller (−0.70, CI touching zero), slightly weakening the negotiating hand with no partner yet signed.
  17. Avoid UPDATE: CervoMed (CRVO) - The Going Concern Flag Is Back Up The Q3 10-Q reinstates the going-concern warning and discloses an Armistice Capital lawsuit over the June raise, removing the sole condition that justified the August upgrade to Watch List.
  18. Avoid UPDATE: CervoMed (CRVO) - The Whisper Gets a Dose-Response The 24-week nfvPPA data shows NfL stable overall with a decline only in the top-exposure tertile (n=6), strengthening the dosing story but leaving the going-concern flag, Armistice lawsuit, and missing partner unchanged.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (56)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)